BTIG Research forecasts strong price appreciation for Kymera Therapeutics (NASDAQ:KYMR) stock. October 29, 2026 Key points. * BTIG Research raised Kymera Therapeutics' price target to $139 from $134 and reiterated a "Buy" rating, implying 13.38% upside from the prior close. * Analyst sentiment remains broadly positive: Kymera has a consensus "Moderate Buy" rating and an average price target of $137.32, with other targets ranging as high as $180. * Kymera reported a quarterly loss of $1.32 per share, missing the $1.26 consensus estimate, while revenue was essentially flat year over year and the company continued to post substantial losses. * Interested in Kymera Therapeutics? Here are five stocks we like better. Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) had its price objective raised by equities research analysts at BTIG Research from $134.00 to $139.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's target price would indicate a potential upside of 13.38% from the company's previous close. KYMR has been the subject of several other research reports. Loop Capital set a $132.00 target price on shares of Kymera Therapeutics in a research report on Thursday. Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $180.00 price target for the company in a research note on Thursday, September 10th. Guggenheim boosted their price objective on Kymera Therapeutics from $135.00 to $170.00 and gave the company a "buy" rating in a report on Monday, August 31st. Oppenheimer restated an "outperform" rating and set a $140.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Finally, Wells Fargo & Company increased their target price on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $137.32. Kymera Therapeutics stock performance. Kymera Therapeutics stock traded up $0.09 during midday trading on Thursday, reaching $122.60. The stock had a trading volume of 1,045,347 shares, compared to its average volume of 748,981. Kymera Therapeutics has a twelve month low of $55.66 and a twelve month high of $130.05. The stock has a market capitalization of $10.19 billion, a PE ratio of -37.84 and a beta of 1.98. The stock's 50-day simple moving average is $114.92 and its 200 day simple moving average is $95.84. Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. Kymera Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.94) earnings per share. Equities analysts predict that Kymera Therapeutics will post -3.85 earnings per share for the current fiscal year. Insider buying and selling. In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This trade represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 15.98% of the company's stock. Hedge funds weigh in on Kymera Therapeutics. Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Kymera Therapeutics in the 2nd quarter valued at $635,067,000. Merck & Co. Inc. bought a new position in Kymera Therapeutics during the second quarter worth $88,544,161. Bank of America Corp DE bought a new position in Kymera Therapeutics during the second quarter worth $43,378,000. Bank of New York Mellon Corp bought a new position in Kymera Therapeutics during the second quarter worth $24,721,000. Finally, Eagle Health Investments LP acquired a new stake in Kymera Therapeutics in the second quarter worth $19,052,000. More Kymera Therapeutics news. Here are the key news stories impacting Kymera Therapeutics this week: * Promising KT-579 Phase 1 results: Kymera reported deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The data support further development of KT-579 as an oral treatment for immunological diseases. * Analyst remains constructive: Morgan Stanley reportedly expects KYMR's stock price to rise, providing some support for investor sentiment following the clinical update. * KT-621 remains an investor focus: Preview coverage highlighted the company's KT-621 program ahead of the earnings release, but the supplied reports do not provide new efficacy or regulatory data for the program. * Quarterly loss exceeded expectations: Kymera reported a third-quarter loss of $1.32 per share, worse than the $1.26 consensus estimate and below the $0.94 loss recorded a year earlier. Revenue was essentially flat year over year, offering little financial offset to continued research and development spending. * Net loss widened: The broader earnings coverage reinforced the deteriorating profitability trend, with a negative net margin and no near-term earnings support. Investors may therefore remain sensitive to clinical execution, pipeline progress and cash-burn expectations. About Kymera Therapeutics. Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell's natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities. The company's research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Kymera Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list. While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat

Kymera Therapeutics (KYMR) stock nearly doubled in a year, turning $10,000 held on October 22, 2025 into about $19,850 by October 23, 2026. That beat the S&P 500's 15.1% return, driven largely by KT-621, an oral STAT6 degrader the company is testing in atopic dermatitis and asthma. Kymera signalled its immunology focus on October 31, 2024. In June 2025, it said healthy-volunteer results surpassed its target, and investors bought $250.8 million of new shares at $44.00 each. In December 2025, it sold about $692 million of stock at $86 a share. In March 2026, Kymera reported positive Phase 1b results in patients with atopic dermatitis. It said on August 5, 2026 that enrollment in its Phase 2b trial was complete nearly six months early, with data expected by year-end 2026. The stock closed at $110.76, below its August 19, 2026 high of $127.31.

HC Wainwright issues negative outlook for KYMR earnings. August 10, 2026 Key points. * HC Wainwright cut its Kymera Therapeutics earnings forecasts, lowering its Q3 2026 EPS estimate to a loss of $1.04 from $0.69 and projecting continued losses through 2029. Its fiscal 2030 estimate was reduced to $0.22 per share, signaling a more cautious profitability outlook. * Kymera's latest quarterly results were better than expected: the company reported a $0.62 per-share loss versus the $0.71 consensus estimate, while revenue reached $65 million and surged 465.2% year over year. * Despite the negative earnings revisions, analyst sentiment remains broadly positive, with 20 Buy ratings, two Holds and one Sell, producing a "Moderate Buy" consensus and an average price target of $125.65. * MarketBeat previews the top five stocks to own by September 1st. Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Kymera Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($1.04) for the quarter, down from their previous forecast of ($0.69). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($4.22) EPS, FY2028 earnings at ($4.32) EPS, FY2029 earnings at ($3.70) EPS and FY2030 earnings at $0.22 EPS. Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same quarter in the previous year, the business earned ($0.95) EPS. The firm's revenue for the quarter was up 465.2% on a year-over-year basis. A number of other equities research analysts have also recently weighed in on KYMR. Oppenheimer restated an "outperform" rating and set a $125.00 price objective on shares of Kymera Therapeutics in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Truist Financial raised their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a "buy" rating in a research note on Monday, June 29th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and upped their price target for the stock from $106.00 to $115.00 in a research note on Monday, July 13th. Finally, Barclays increased their price objective on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an "overweight" rating in a report on Thursday. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $125.65. Discover more MarketBeat All Access Cryptocurrency News Market Cap Calculator Kymera Therapeutics stock performance. NASDAQ:KYMR opened at $107.52 on Monday. The stock has a market cap of $8.94 billion, a price-to-earnings ratio of -33.19 and a beta of 1.95. Kymera Therapeutics has a 1 year low of $36.65 and a 1 year high of $130.05. The business has a fifty day moving average of $101.31 and a 200-day moving average of $88.93. Insider transactions at Kymera Therapeutics. In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total value of $168,142,200.00. Following the completion of the sale, the director directly owned 240,123 shares of the company's stock, valued at approximately $25,573,099.50. This represents a 86.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nello Mainolfi sold 80,000 shares of the firm's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,604,813 shares of company stock worth $387,557,004. Corporate insiders own 15.98% of the company's stock. Institutional trading of Kymera Therapeutics. Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP grew its position in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock worth $581,610,000 after acquiring an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock worth $479,258,000 after acquiring an additional 1,061,957 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth $635,067,000. Key stories impacting Kymera Therapeutics. Here are the key news stories impacting Kymera Therapeutics this week: * Positive Sentiment: Kymera's latest quarterly results provided support for the stock: the company reported a smaller-than-expected loss and revenue of $65 million, far above analyst expectations. Revenue increased 465% year over year, highlighting growing commercial and partnership-related momentum. * Neutral Sentiment: Recent coverage describes conflicting analyst sentiment toward Kymera, suggesting that optimism over its therapeutic pipeline and growth prospects is being balanced by concerns about continued research-and-development spending and losses. Analysts Have Conflicting Sentiments on These Healthcare Companies * Neutral Sentiment: Kymera is drawing fresh investor attention, likely reflecting interest in its targeted protein degradation platform and pipeline. However, the available report does not identify a specific new clinical, regulatory, or partnership catalyst. Why Kymera Therapeutics Is Drawing Fresh Attention This Week? * Negative Sentiment: Brookline Capital Markets lowered its third-quarter EPS estimate for Kymera, adding to concerns that near-term losses may be larger than previously expected. KYMR Q3 EPS Estimate Lowered by Brookline Capital Markets * Negative Sentiment: HC Wainwright reduced its EPS forecasts for the third and fourth quarters of 2026 and for fiscal 2026 through 2029. Its fiscal 2030 estimate was also cut from $1.07 to $0.22 per share, signaling a more conservative view of Kymera's path to profitability. About Kymera Therapeutics. Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small-molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease-causing proteins. The company's proprietary Pegasus(TM) platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas. The company's pipeline emphasizes immunology and oncology. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Kymera Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list. While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.